Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  American Journal of Kidney Diseases

• Publication date

  2004-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/J.AJKD.2004.07.021PMID 15492948
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

  2003cited by this paper
• Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

  2003cited by this paper
• Direct Actions of Urotensin II on the Heart: Implications for Cardiac Fibrosis and Hypertrophy

  2003cited by this paper
• Over-expression of platelet-derived growth factor in human diabetic nephropathy.

  2003cited by this paper
• Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney.

  2003cited by this paper
• Increased plasma urotensin II levels in patients with diabetes mellitus.

  2003cited by this paper
• Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1.

  2003cited by this paper
• Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma

  2002cited by this paper
• Plasma urotensin II in heart failure.

  2002cited by this paper
• Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure.

  2002cited by this paper
• Congestive heart failure and expression of myocardial urotensin II.

  2002cited by this paper
• Role of urotensin II in patients on dialysis.

  2001cited by this paper
• Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues

  2001cited by this paper
• Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries.

  2001cited by this paper
• Human urotensin‐II is an endothelium‐dependent vasodilator in rat small arteries

  2000cited by this paper
• Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate.

  2000cited by this paper
• The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?

  1999cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999cited by this paper
• Demonstration of the proliferation marker Ki-67 in renal biopsies: correlation to clinical findings.

  1997cited by this paper
• Altered expression of fibrogenic growth factors in IgA nephropathy and focal and segmental glomerulosclerosis.

  1997cited by this paper
• Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates.

  1996cited by this paper
• Improved purification and yields of RNA by RNeasy.

  1996cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper

• Urotensin II system in chronic kidney disease

  2024cites this paper
• The role of irisin in kidney diseases.

  2024cites this paper
• 2-{N-[(2,4,5-trichlorophenoxy) acetyl]-N-methylamino}-3-pyrrolidinepropanamide analogs as potential antagonists of Urotensin II receptor

  2023cites this paper
• Loss of urotensin II receptor diminishes hyperglycemia and kidney injury in streptozotocin-treated mice.

  2022cites this paper
• The network map of urotensin-II mediated signaling pathway in physiological and pathological conditions.

  2022cites this paper
• Endoplasmic Reticulum Stress in Diabetic Nephrology: Regulation, Pathological Role, and Therapeutic Potential

  2021cites this paper
• An Investigation of Saliva and Plasma Levels of Urotensin-2 in Recently Diagnosed Type 2 Diabetes Mellitus Patients on Metformin Treatment.

  2020cites this paper
• Glucose and Blood Pressure-Dependent Pathways–The Progression of Diabetic Kidney Disease

  2020cites this paper
• Potential Therapeutic Value of Urotensin II Receptor Antagonist in Chronic Kidney Disease and Associated Comorbidities

  2020cites this paper
• Urotensin II in the development and progression of chronic kidney disease following ⅚ nephrectomy in the rat

  2019cites this paper
• Synthesis and SAR of 5-aryl-furan-2-carboxamide derivatives as potent urotensin-II receptor antagonists.

  2019cites this paper
• Urotensin receptor antagonist palosuran attenuates cyclosporine-a-induced nephrotoxicity in rats.

  2019cites this paper
• The Endocrine Kidney

  2019cites this paper
• Silymarin ameliorates expression of urotensin II (U-II) and its receptor (UTR) and attenuates toxic oxidative stress in the heart of rats with type 2 diabetes.

  2018cites this paper
• Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects

  2018cites this paper
• Urotensin II-induced store-operated Ca2+ entry contributes to glomerular mesangial cell proliferation and extracellular matrix protein production under high glucose conditions

  2017cites this paper
• The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features

  2017cites this paper
• vasoconstrictionangiotensin II and in urotensin II-induced Role of PKC in the novel synergistic action of urotensin II

  2016cites this paper
• Benzo[b]thiophene-2-carboxamide derivatives as potent urotensin-II receptor antagonists.

  2016cites this paper
• Role of urotensin II in advanced glycation end product-induced extracellular matrix synthesis in rat proximal tubular epithelial cells.

  2016cites this paper
• Urotensin II Induces ER Stress and EMT and Increase Extracellular Matrix Production in Renal Tubular Epithelial Cell in Early Diabetic Mice

  2016cites this paper
• 1,3,4‐Thiadiazol‐2‐amine Derivatives as Urotensin‐II Receptor (UT) Antagonists

  2015cites this paper
• Palosuran: clinical pharmacology of a urotensin-II receptor antagonist in Type 2 Diabetes Mellitus

  2015influential citation
• A Systems Biology Overview on Human Diabetic Nephropathy: From Genetic Susceptibility to Post-Transcriptional and Post-Translational Modifications

  2015cites this paper
• Urotensin-II level and its association with oxidative stress in early diabetic nephropathy.

  2015cites this paper
• International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function

  2015cites this paper
• Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists.

  2014cites this paper
• Can early myocardial infarction-related deaths be diagnosed using postmortem urotensin receptor expression levels?

  2014cites this paper
• Expression of Urotensin II During Focal Cerebral Ischemic in Diabetic Rats

  2014cites this paper
• Pressor and renal regional hemodynamic effects of urotensin II in neonatal pigs

  2013cites this paper
• Effect of KIOM-79 on Diabetes-Induced Myocardial Fibrosis in Zucker Diabetic Fatty Rats

  2013cites this paper
• Analysis of genetic variation within urotensin-II system in regulation of blood pressure and renal function

  2013influential citation
• Urotensin II and the kidney

  2013cites this paper
• Emerging drugs for managing kidney disease in patients with diabetes

  2013cites this paper
• Effects of Advanced Glycation End Products on the mRNA Expression of Urotensin II and G Protein-Coupled Receptor in Rat Mesangial Cells

  2013cites this paper
• Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update.

  2013cites this paper
• Urotensin-II System in Genetic Control of Blood Pressure and Renal Function

  2013cites this paper
• Vasoactive Molecules and the Kidney

  2012cites this paper
• Experimental Study of TFGs on Cardiac Fibroblast Transdifferentiation and Its Mechanism

  2012cites this paper
• Association Between Thr21Met and Ser89Asn Polymorphisms of the Urotensin-II (UTS2) Gene, Diabetes Mellitus, and Diabetic Retinopathy

  2012cites this paper
• Effects of TFGs on cultured interstitial fibroblasts of rats' myocardium

  2011cites this paper
• Renal impairment, hypertension and plasma urotensin II.

  2011cites this paper
• The effects of urotensin II and its receptor in rat renal interstitial fibrosis

  2011cites this paper
• Development of Filtration-Based Time-Resolved Fluorescence Assay for the High-Throughput Screening of Urotensin II Receptor Antagonist

  2011cites this paper
• Potential Clinical Implications of the Urotensin II Receptor Antagonists

  2011cites this paper
• Untersuchung der proteolytischen Prozessierung von humanen Urotensin-Peptiden

  2010cites this paper
• Role of urotensin II in health and disease.

  2010cites this paper
• Urotensin 2 and retinoic acid receptor alpha (RARA) gene expression in IgA nephropathy.

  2010cites this paper
• Urotensin-II receptor modulators as potential drugs.

  2010cites this paper
• Suche, Reinigung und Identifizierung eines Urotensin II metabolisierenden Enzyms

  2010cites this paper
• Role of Novel Biomarkers in Chronic Kidney Disease: Urotensin II

  2010cites this paper
• Pharmacokinetics and Pharmacodynamics of the Urotensin‐II Receptor Antagonist Palosuran in Healthy Male Subjects

  2009cites this paper
• Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.

  2009cites this paper
• Generation of novel, potent urotensin-II receptor antagonists by alkylation-cyclization of isoindolinone C3-carbanions

  2009cites this paper
• Increased expression of urotensin II-related peptide and its receptor in kidney with hypertension or renal failure.

  2009cites this paper
• The renin-angiotensin system, adrenomedullins and urotensin II in the kidney: possible renoprotection via the kidney peptide systems.

  2009cites this paper
• Elevated expression of urotensin II and its receptor in great artery of type 2 diabetes and its significance.

  2009cites this paper
• Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases.

  2009cites this paper
• Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits.

  2009cites this paper
• Elevated expression of urotensin II and its receptor in skeletal muscle of diabetic mouse.

  2009cites this paper
• N-alkyl-5H-pyrido[4,3-b]indol-1-amines and derivatives as novel urotensin-II receptor antagonists.

  2008cites this paper
• Vasoactive Hormones and the Diabetic Kidney

  2008cites this paper
• 2-Aminomethyl piperidines as novel urotensin-II receptor antagonists.

  2008cites this paper
• Urotensin II: lessons from comparative studies for general endocrinology.

  2008cites this paper
• Hemodynamic-independent anti-natriuretic effect of urotensin II in spontaneously hypertensive rats.

  2008cites this paper
• Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy.

  2008cites this paper
• Urotensin II in cardiovascular regulation

  2008cites this paper
• Comparative understanding of UTS2 and UTS2R genes for their involvement in type 2 diabetes mellitus

  2008cites this paper
• Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes.

  2008cites this paper
• Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction.

  2008influential citation
• Development of potent and selective small-molecule human Urotensin-II antagonists.

  2008cites this paper
• Urotensin II: a cardiovascular and renal update

  2008cites this paper
• Aminomethylpiperazines as selective urotensin antagonists.

  2008cites this paper
• Structure-activity relationships of urotensin II and URP.

  2008cites this paper
• EFFECT OF UROTENSIN II ON SKIN MICROVESSEL TONE IN DIABETIC PATIENTS WITHOUT HEART FAILURE OR ESSENTIAL HYPERTENSION

  2008cites this paper
• Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?

  2008cites this paper
• The role of urotensin II in the metabolic syndrome.

  2008cites this paper
• Comparative understanding of UTS 2 and UTS 2 R genes for their involvement in type 2 diabetes mellitus

  2008cites this paper
• Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease.

  2008cites this paper
• Cardiorenovascular effects of urotensin II and the relevance of the UT receptor.

  2008cites this paper
• Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.

  2008cites this paper
• Urotensin II: A New Pharmacologic Target in the Treatment of Cardiovascular Disease

  2008cites this paper
• Strategies to optimize renoprotective therapy in proteinuric renal patients

  2008cites this paper
• Synthèse de ligands du récepteur de l'Urotensine II et des récepteurs de la Mélatonine : composés à noyau pyrido[2,3-d]pyrimidine ou imidazo[1,2-a]pyridine

  2008cites this paper
• Effect of the urotensin receptor antagonist palosuran on albuminuria in hypertensive patients with type 2 diabetic nephropathy: results from the PROLONG proof-of-concept study

  2008cites this paper
• Urotensin‐II Induces Ear Flushing in Rats

  2007cites this paper
• Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction.

  2007cites this paper
• Urotensin-II in the lung: A matter for vascular remodelling and pulmonary hypertension?

  2007cites this paper
• Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?

  2007cites this paper
• Design, parallel synthesis and SAR of novel urotensin II receptor agonists.

  2007cites this paper
• Diabetic nephropathy: where hemodynamics meets metabolism.

  2007cites this paper
• RESEARCH PAPER Urotensin-II Induces Ear Flushing in Rats

  2007cites this paper
• Therapeutic potential of blockade of the Urotensin II system in systemic hypertension

  2007cites this paper
• Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts.

  2006cites this paper
• Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig.

  2006cites this paper
• Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease.

  2006cites this paper
• Human Urotensin II as a Link between Hypertension and Coronary Artery Disease

  2006cites this paper
• The role of urotensin II in cardiovascular and renal physiology and diseases

  2006influential citation
• Novel potent and efficacious nonpeptidic urotensin II receptor agonists.

  2006cites this paper
• Identification and characterization of binding sites for human urotensin-II in Sprague–Dawley rat renal medulla using quantitative receptor autoradiography

  2006cites this paper